Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, DENTSPLY Sirona Inc’s stock clocked out at $11.29, up 1.80% from its previous closing price of $11.09. In other words, the price has increased by $1.80 from its previous closing price. On the day, 3.52 million shares were traded. XRAY stock price reached its highest trading level at $11.475 during the session, while it also had its lowest trading level at $11.025.
Ratios:
To gain a deeper understanding of XRAY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.16. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.47. In the meantime, Its Debt-to-Equity ratio is 1.68 whereas as Long-Term Debt/Eq ratio is at 1.42.
On April 15, 2025, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 24 ’25 when VARON LESLIE F bought 9,337 shares for $10.71 per share. The transaction valued at 99,999 led to the insider holds 57,343 shares of the business.
LUCIER GREGORY T bought 15,142 shares of XRAY for $249,994 on Mar 03 ’25. The Director now owns 81,971 shares after completing the transaction at $16.51 per share. On Jan 27 ’25, another insider, Coleman Glenn, who serves as the Former Officer of the company, bought 15,759 shares for $19.75 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 2252941824 and an Enterprise Value of 4383941632. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62 while its Price-to-Book (P/B) ratio in mrq is 1.52. Its current Enterprise Value per Revenue stands at 1.21 whereas that against EBITDA is 7.175.
Stock Price History:
The Beta on a monthly basis for XRAY is 1.03, which has changed by -0.42544532 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, XRAY has reached a high of $20.59, while it has fallen to a 52-week low of $9.85. The 50-Day Moving Average of the stock is -6.95%, while the 200-Day Moving Average is calculated to be -22.05%.
Shares Statistics:
It appears that XRAY traded 3.45M shares on average per day over the past three months and 4078900 shares per day over the past ten days. A total of 199.50M shares are outstanding, with a floating share count of 198.18M. Insiders hold about 0.69% of the company’s shares, while institutions hold 105.50% stake in the company. Shares short for XRAY as of 1763078400 were 13457231 with a Short Ratio of 3.90, compared to 1760486400 on 8961408. Therefore, it implies a Short% of Shares Outstanding of 13457231 and a Short% of Float of 7.5200000000000005.
Dividends & Splits
With its trailing 12-month dividend rate of 0.64, XRAY has a forward annual dividend rate of 0.64. Against a Trailing Annual Dividend Yield of 0.057709645. The stock’s 5-year Average Dividend Yield is 1.89.
Earnings Estimates
. The current rating of DENTSPLY Sirona Inc (XRAY) reflects the combined expertise of 15.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.39, with high estimates of $0.55 and low estimates of $0.28.
Analysts are recommending an EPS of between $1.83 and $1.59 for the fiscal current year, implying an average EPS of $1.62. EPS for the following year is $1.58, with 16.0 analysts recommending between $1.79 and $1.15.
Revenue Estimates
In. The current quarter, 13 analysts expect revenue to total $924.64M. It ranges from a high estimate of $964M to a low estimate of $892M. As of. The current estimate, DENTSPLY Sirona Inc’s year-ago sales were $905MFor the next quarter, 13 analysts are estimating revenue of $898.84M. There is a high estimate of $926.15M for the next quarter, whereas the lowest estimate is $887M.
A total of 17 analysts have provided revenue estimates for XRAY’s current fiscal year. The highest revenue estimate was $3.68B, while the lowest revenue estimate was $3.61B, resulting in an average revenue estimate of $3.64B. In the same quarter a year ago, actual revenue was $3.79BBased on 16 analysts’ estimates, the company’s revenue will be $3.67B in the next fiscal year. The high estimate is $3.77B and the low estimate is $3.55B.
